Clinical Trial Search

Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons

Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…

Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043

Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…

Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants

Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…

Primary: Acceptability of Self-Collection Paired With Mobile Mammography — 33 Participants

Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants

Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…

Primary: HPV Identification — 95; 142; 78 biopsies

Primary: Number of Participants Who Scheduled or Completed Cervical Cancer Screening — 28; 21 Participants

Primary: Number of Female Subjects With Overall Vaccine Effectiveness Against Genital Infection With Human Papilloma Virus (HPV)-16/18 Types in Cervarix/Engerix-B B Group Versus…

Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants

Primary: Tumor Response — 1; 7; 17; 34 participants

Primary: Number Seropositive for HPV16 at 36 Months — 538; 366 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0 Participants

Primary: Histologic Regression — 40; 34.1 percentage of participants

Primary: Number of Patients With Dose-limiting Toxicities, as Assessed by CTCAE v 4.0 — 0 Participants

Primary: Number of Seroconverted (SCR) Subjects for Anti-Human Papillomavirus Type 16 (Anti-HPV-16) and Anti-Human Papillomavirus Type 18 (Anti-HPV-18) — 118; 127; 126; 371…

Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants

Primary: Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18) — 0; 15; 0; 11 Participants

Primary: Safety and Feasibility as Assessed by Number of Participants With Treatment-related Adverse Events — 5; 3; 8; 7 Participants

Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants

Primary: Progression-free Survival Greater Than 6 Months — 30; 5 participants

Primary: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection — 190; 181 Participants

Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms — 46; 18; 19; 2 Participants

Primary: Complete Response - Clearance of Oncogenic Human Papillomavirus (HPV) and Complete Colposcopic, Histologic and Cytologic Clearance of Disease — 7; 6 participants

Primary: Number of Patients With Measurable Concentration of Gemcitabine in Uterine Vein (dFdC) — 5 Participants

Primary: Cervical HSIL — 46; 39 Participants — p=.29

Primary: Safety and Toxicity — 0; 0; 0 Participants